Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
13 Novembro 2024 - 6:30PM
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases, announced today
that Jack Khattar, President and CEO of Supernus Pharmaceuticals,
will participate in a fireside chat at the Jefferies London
Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m.
GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United
Kingdom.
Investors interested in arranging a meeting with
company management during the conference should contact the
Jefferies conference coordinator. A live audio webcast of the
presentation can be accessed here or by visiting Events &
Presentations in the Investor Relations section on the Company's
website at www.supernus.com. An archived replay of the webcast will
be available for 60 days on the Company's website following the
conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes
approved treatments for epilepsy, migraine, ADHD, hypomobility in
Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea,
and dyskinesia in PD patients receiving levodopa-based therapy. We
are developing a broad range of novel, first in class CNS product
candidates including new potential treatments for hypomobility in
PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements do not convey historical
information but relate to predicted or potential future events that
are based upon management's current expectations. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by
such statements. In addition to the factors mentioned in this press
release, such risks and uncertainties include, but are not limited
to, the Company’s reporting on preliminary and exploratory open
label clinical study on SPN-820, the Company’s ability to sustain
and increase its profitability; the Company’s ability to raise
sufficient capital to fully implement its corporate strategy; the
implementation of the Company’s corporate strategy; the Company’s
future financial performance and projected expenditures; the
Company’s ability to increase the number of prescriptions written
for each of its products and the products of its subsidiaries; the
Company’s ability to increase net revenue; the Company’s ability to
commercialize its products and the products of its subsidiaries;
the Company’s ability to enter into future collaborations with
pharmaceutical companies and academic institutions or to obtain
funding from government agencies; the Company’s ability to conduct
and progress product research and development activities, including
the timing and progress of the Company’s clinical trials, and
projected expenditures; the Company’s ability to receive, and the
timing of any receipt of, regulatory approvals to develop and
commercialize the Company’s product candidates including SPN-820
and SPN-830; the Company’s ability to protect its intellectual
property and the intellectual property of its subsidiaries and
operate its business without infringing upon the intellectual
property rights of others; the Company’s expectations regarding
federal, state and foreign regulatory requirements; the therapeutic
benefits, effectiveness and safety of the Company’s product
candidates including SPN-820; the accuracy of the Company’s
estimates of the size and characteristics of the markets that may
be addressed by its product candidates; the Company’s ability to
increase its manufacturing capabilities for its products and
product candidates including SPN-820; the Company’s projected
markets and growth in markets; the Company’s product formulations
and patient needs and potential funding sources; the Company’s
staffing needs; and other risk factors set forth from time to time
in the Company’s filings with the Securities and Exchange
Commission made pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended. The Company undertakes
no obligation to update the information in this press release to
reflect events or circumstances after the date hereof or to reflect
the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO Timothy C. Dec, Senior
Vice President and CFO Supernus Pharmaceuticals,
Inc. (301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo ICR Healthcare(443)
213-0505 Peter.Vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024